A detailed history of Virtu Financial LLC transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Virtu Financial LLC holds 94,099 shares of IOVA stock, worth $808,310. This represents 0.05% of its overall portfolio holdings.

Number of Shares
94,099
Holding current value
$808,310
% of portfolio
0.05%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$7.78 - $14.19 $732,090 - $1.34 Million
94,099 New
94,099 $755,000
Q2 2023

Jul 27, 2023

BUY
$5.36 - $9.06 $117,121 - $197,970
21,851 New
21,851 $154,000
Q2 2021

Sep 17, 2021

SELL
$16.33 - $33.07 $693,698 - $1.4 Million
-42,480 Closed
0 $0
Q1 2021

May 19, 2021

BUY
$28.67 - $52.59 $1.03 Million - $1.89 Million
35,981 Added 553.64%
42,480 $1.35 Million
Q4 2020

Feb 24, 2021

SELL
$28.04 - $50.26 $342,424 - $613,775
-12,212 Reduced 65.27%
6,499 $302,000
Q3 2020

Dec 11, 2020

SELL
$27.75 - $36.3 $31,080 - $40,656
-1,120 Reduced 5.65%
18,711 $616,000
Q2 2020

Aug 07, 2020

BUY
$27.21 - $41.0 $539,601 - $813,071
19,831 New
19,831 $544,000
Q4 2019

Feb 04, 2020

SELL
$17.95 - $29.41 $212,061 - $347,449
-11,814 Closed
0 $0
Q3 2019

Nov 20, 2019

BUY
$17.99 - $26.0 $212,533 - $307,164
11,814 New
11,814 $215,000
Q2 2019

Aug 13, 2019

SELL
$9.78 - $24.52 $101,565 - $254,640
-10,385 Closed
0 $0
Q1 2019

Apr 12, 2019

BUY
$8.41 - $11.26 $87,337 - $116,935
10,385 New
10,385 $99,000
Q4 2018

Jan 16, 2019

SELL
$7.51 - $11.93 $456,698 - $725,487
-60,812 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$11.25 - $17.7 $684,135 - $1.08 Million
60,812 New
60,812 $684,000
Q1 2018

May 14, 2018

SELL
$8.1 - $19.5 $185,174 - $445,789
-22,861 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$6.65 - $9.25 $152,025 - $211,464
22,861
22,861 $183,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.36B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.